NovaBridge Biosciences
NBPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 16, 2026 | H.C. Wainwright | Andres Maldonado | $9.00(+215%) | $2.86 | StreetInsider |
| Oct 27, 2025 | H.C. Wainwright | Andrew Fein | $7.00(+55%) | $4.52 | StreetInsider |
| Oct 3, 2025 | Leerink Partners | $9.00(+118%) | $4.13 | TheFly | |
| Sep 10, 2025 | New Street | $7.00(+67%) | $4.18 | TheFly | |
| Aug 28, 2025 | Loop Capital Markets | Kumaraguru Raja | $8.00(+88%) | $4.25 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 6, 2026 |
| BTIG | maintain | Buy | Oct 24, 2025 |
| BTIG | maintain | Buy | Oct 17, 2025 |
| BTIG | maintain | Buy | Sep 10, 2025 |
| Needham | maintain | Buy | Sep 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2025 |
| Needham | maintain | Buy | Aug 20, 2025 |
| Needham | maintain | Buy | Jul 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2025 |
| Needham | maintain | Buy | Jun 27, 2025 |
| Needham | maintain | Buy | Sep 24, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Sep 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2023 |
| Needham | maintain | Buy | Aug 17, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 17, 2023 |
| Needham | maintain | Buy | Jun 4, 2023 |
| Needham | maintain | Buy | Apr 19, 2023 |
| Needham | maintain | Buy | Apr 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2023 |
| Piper Sandler | maintain | Overweight | Apr 2, 2023 |
| Needham | maintain | Buy | Aug 30, 2022 |
| HC Wainwright & Co. | maintain | Buy | Aug 30, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 20, 2026 | $-0.02 | $-0.03 | — | — |
| Jul 30, 2026 | $-0.22 | $-0.01 | — | — |
| Dec 18, 2025 | $-0.03 | $-0.06 | — | — |
| Aug 26, 2025 | $-0.03 | $-0.06 | — | — |
| May 15, 2025 | $-0.02 | $-0.06 | — | — |
| Mar 31, 2025 | $-0.06 | $-0.06 | — | $1.5M |
| Nov 14, 2024 | $-0.25 | $-0.16 | — | $1.5M |
| Aug 28, 2024 | $-0.07 | $-0.51 | $9.9M | $1.5M |
News
NovaBridge Biosciences (NBP) Discusses Mature Givastomig Data and Registrational Development Strategy Transcript
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma
YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest dose cohort after an 8-week course HT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis, building …
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage program, expanding the Company's ophthalmology portfolio beyond retinal vascular disease into ocular surface disease HT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis ROCKVILLE, Md., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Visara, Inc…
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA), will be presented at the Europe…
I-Mab (NASDAQ: NBP - Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ: VBIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Volatility and Risk I-Mab has
ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the “Board”) as an independent director, and as a member of both the Audit Committee and the Compensation Committee, effective immediatel…
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company's leadership will participate in the following investor conferences in September 2026: Conference details: Cantor 2026 Global Healthcare Conference Format: Fireside Chat and one-on-on…
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today reported financial results for the six months ended June 30, 2026, and provided a business update. During the first half of 2026, the Company continued executing its strategic priorities by progressing key clin…
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.